Trial Profile

MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Margetuximab (Primary) ; Trastuzumab (Primary) ; Paclitaxel; Pertuzumab
Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms MARGOT

15 May 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Oct 2024.
15 May 2024 Status changed from recruiting to active, no longer recruiting.
28 Jul 2020 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com